TLC BioSciences Income Statement

Financials in millions TWD. Fiscal year is January - December.

Millions TWD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024
Revenue	78.44	89.44	189.17
Revenue Growth	-	-52.72%	-
Cost of Revenue	29.82	15.51	62.92
Gross Profit	48.62	73.93	126.25
Selling, General & Admin	538.28	133.39	233.39
Research & Development	1,230	579.59	781.47
Operating Expenses	1,768	712.97	1,015
Operating Income	-1,720	-639.05	-888.62
Interest Expense	-130.82	-126.04	-144.96
Interest & Investment Income	22.09	34.26	74
Other Non Operating Income (Expenses)	273.88	82.19	-1,250
Pretax Income	-1,816	-648.64	-2,210
Income Tax Expense	4.66	4.61	0.67
Earnings From Continuing Operations	-1,821	-653.25	-2,211
Minority Interest in Earnings	-	-	24.87
Net Income	-1,821	-653.25	-2,186
Net Income to Common	-1,821	-653.25	-2,186
Net Income Growth	-	-	-
Shares Outstanding (Basic)	96	83	77
Shares Outstanding (Diluted)	96	83	77
Shares Change	-	8.65%	-
EPS (Basic)	-18.95	-7.84	-28.50
EPS (Diluted)	-18.95	-7.84	-28.50
EPS Growth	-	-	-

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024
Free Cash Flow	-962.49	-464.99	-926.82
Free Cash Flow Per Share	-10.02	-5.58	-12.09
Gross Margin	61.99%	82.66%	66.74%
Operating Margin	-2192.34%	-714.51%	-469.76%
Profit Margin	-2321.10%	-730.39%	-1155.44%
Free Cash Flow Margin	-1227.05%	-519.91%	-489.95%
EBITDA	-1,652	-571.17	-817.99
D&A For EBITDA	67.18	67.88	70.63
EBIT	-1,720	-639.05	-888.62